FDA Clears Red-Light Gel Treatment for Common Skin Cancer

A Red-Light Gel Treatment for common skin cancer has just won federal clearance. On September 14, 2026, the Food and Drug Administration approved Ameluz gel combined with red-light photodynamic therapy for adults with superficial basal cell carcinoma, the most frequently diagnosed form of skin cancer. It is the first time the agency has approved a photodynamic therapy to treat a skin cancer, according to Dermatology Times.

The treatment works in two steps at a dermatologist's office, with no cutting involved. A gel containing aminolevulinic acid hydrochloride is spread over the lesion and the surrounding skin, where abnormal cells absorb it more readily and become sensitive to specific wavelengths of light. After a waiting period, the area is exposed to a red-light lamp from the BF-RhodoLED series, which activates the drug and triggers a reaction that destroys the targeted cells. A CURE Today explainer notes that while this form of skin cancer rarely spreads elsewhere in the body, it can grow into surrounding tissue and cause real damage if left untreated. Patients can receive up to two treatment cycles, each made up of two light sessions spaced a week or two apart.

The evidence behind the approval came from a randomized, double-blind phase three trial of one hundred eighty-seven adults with confirmed superficial basal cell carcinoma on the face, forehead, scalp, arms, legs, neck or trunk. Twelve weeks after the final light cycle, sixty-six percent of patients who received the gel plus light therapy achieved a complete clinical and histological response of the main treated lesion, compared with five percent of those who received light therapy with a placebo gel. When doctors looked at all treated lesions, eighty-three percent of the treatment-group patients showed full clinical clearance, and most of those lesions earned a good or very good cosmetic rating from the physicians who examined them.

Why a non-surgical option matters

Basal cell carcinoma is usually handled with surgery, including precise procedures like Mohs surgery, which removes the tumor layer by layer. That approach is effective but leaves scars and can mean stitches, follow-up visits and time off work, which is a heavy option for people with many lesions or spots in places where appearance matters. The new Red-Light Gel Treatment gives dermatologists a tissue-sparing alternative delivered in the office, which may matter especially for patients with multiple spots, lesions in cosmetically sensitive locations, or reasons to avoid surgery, according to AIM at Skin Cancer's coverage of the decision.

"This FDA approval gives us a rigorously studied, nonsurgical option that we can deliver in our office," said M. Shane Chapman, a dermatologist quoted in the manufacturer's announcement. Hermann Luebbert, chief executive officer and chairman of Biofrontera, called the decision a defining milestone and noted the platform is now the first and only photodynamic therapy approved in the United States to treat a skin cancer. The company plans to roll out the new indication between late 2026 and the first quarter of 2027 using the same gel and lamp already approved for precancerous lesions.

What it does not cover

The approval has clear boundaries. Not everyone will be offered the Red-Light Gel Treatment: it applies only to superficial basal cell carcinoma in adults, not to other skin cancers or to deeper subtypes of the disease, and a dermatologist still needs to confirm the diagnosis before treatment. The full prescribing information published on the FDA's drug database spells out exactly which lesions qualify. The most common side effects were reactions at the application site, including redness, swelling and stinging or burning during the light treatment — uncomfortable but consistent with the therapy's known safety profile. Surgery remains the standard for many cases, and the new option is best understood as another tool in the dermatology office rather than a replacement for the scalpel.

The approval continues a run of fast-moving developments in skin medicine, from gene-targeted cancer research to new diagnostic tests. GenZ NewZ recently reported on a programmable CRISPR approach aimed at the gene fusions behind one in five cancers, and on new data on teen vaping trends with its own skin and health implications. Readers interested in evidence-backed daily habits can also check our look at what coffee research says about healthy aging.

Skin cancer rarely makes headlines the way other diseases do, but its most common form now has a light-based answer for the first time. For patients facing a diagnosis that once meant surgery by default, the arrival of a Red-Light Gel Treatment means the treatment menu just got wider.